4//SEC Filing
Auspex Pharmaceuticals, Inc. 4
Accession 0001209191-15-039545
CIK 0001454189operating
Filed
May 5, 8:00 PM ET
Accepted
May 6, 6:07 PM ET
Size
21.4 KB
Accession
0001209191-15-039545
Insider Transaction Report
Form 4
Stamler David A
Chief Medical Officer
Transactions
- Disposition from Tender
Common Stock
2015-05-05−1,627→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-05-05−25,274→ 0 totalExercise: $0.90Exp: 2021-03-10→ Common Stock (25,274 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-05-05−66,666→ 0 totalExercise: $0.86Exp: 2023-01-28→ Common Stock (66,666 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-05-05−26,219→ 0 totalExercise: $0.54Exp: 2023-09-30→ Common Stock (26,219 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-05-05−60,000→ 0 totalExercise: $59.66Exp: 2025-02-01→ Common Stock (60,000 underlying) - Disposition to Issuer
Restricted Stock Units
2015-05-05−30,000→ 0 total→ Common Stock (30,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2015-05-05−20,623→ 0 totalExercise: $0.90Exp: 2022-01-30→ Common Stock (20,623 underlying)
Footnotes (8)
- [F1]Includes 644 shares of Common Stock that were acquired by the Reporting Person on May 5, 2015 pursuant to the Issuer's Employee Stock Purchase Plan.
- [F2]Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated March 29, 2015, among the Issuer, Teva Pharmaceuticals Industries Ltd. ("Parent"), and Aurum Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub") in exchange for a cash consideration of $101.00 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation (the "Merger").
- [F3]This option, which provided for vesting in 48 equal monthly installments commencing January 15, 2012, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the stock option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
- [F4]This option, which provided for vesting in 48 equal monthly installments commencing January 15, 2013, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the stock option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
- [F5]This option, which provided for vesting of 25% of the shares subject to option on the first anniversary of the vesting commencement date, and the remainder vesting in 36 equal monthly installments thereafter over the following three years, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the stock option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
- [F6]This option, which provided for vesting of 1/48th of the stock option immediately upon grant and 1/48th vesting at the end of each month from February 28, 2015 through December 31, 2018, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the stock option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
- [F7]Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- [F8]These restricted stock units (the "RSUs"), which provided for vesting of 1/4 of shares subject to the RSUs on each March 15, 2016, 2017, 2018 and 2019, were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $101.00 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Documents
Issuer
Auspex Pharmaceuticals, Inc.
CIK 0001454189
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001454189
Filing Metadata
- Form type
- 4
- Filed
- May 5, 8:00 PM ET
- Accepted
- May 6, 6:07 PM ET
- Size
- 21.4 KB